Quote | Baudax Bio Inc. (NYSE:BXRX)
Last: | $ |
---|---|
Change Percent: | 1.59% |
Open: | $8.07 |
Close: | $8.30 |
High: | $8.54 |
Low: | $8.07 |
Volume: | 121,084 |
Last Trade Date Time: | 02/12/2020 04:44:26 pm |
News | Baudax Bio Inc. (NYSE:BXRX)
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Message Board Posts | Baudax Bio Inc. (NYSE:BXRX)
Subject | By | Source | When |
---|---|---|---|
$BXRX Good read | harry crumb | investorshub | 06/25/2023 8:08:41 AM |
The now up | Triple nickle | investorshub | 06/24/2023 7:50:40 AM |
$BXRX The trading | harry crumb | investorshub | 06/22/2023 11:34:41 PM |
$BXRX The gaining last trade up | harry crumb | investorshub | 06/22/2023 5:51:56 PM |
$BXRX news all the way baby | Triple nickle | investorshub | 06/21/2023 12:24:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023